Gil Blum

Recent deaths of two patients with Duchenne muscular dystrophy (DMD) have opened the doors for emerging gene therapies, such as Solid Biosciences Inc's (NASDAQ:SLDB) SGT-003, according to Needham. The Solid Biosciences Analyst: Analyst Gil Blum initiated coverage with a Buy rating and price target...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham. The Recursion Pharmaceuticals Analyst: Analyst Gil Blum maintained a Buy rating and price target of $11. The Recursion...